ID   GLT12_HUMAN             Reviewed;         581 AA.
AC   Q8IXK2; Q5TCF7; Q8NG54; Q96CT9; Q9H771;
DT   16-AUG-2004, integrated into UniProtKB/Swiss-Prot.
DT   20-DEC-2005, sequence version 3.
DT   15-MAR-2017, entry version 143.
DE   RecName: Full=Polypeptide N-acetylgalactosaminyltransferase 12;
DE            EC=2.4.1.41;
DE   AltName: Full=Polypeptide GalNAc transferase 12;
DE            Short=GalNAc-T12;
DE            Short=pp-GaNTase 12;
DE   AltName: Full=Protein-UDP acetylgalactosaminyltransferase 12;
DE   AltName: Full=UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferase 12;
GN   Name=GALNT12;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), ENZYME ACTIVITY, TISSUE
RP   SPECIFICITY, AND VARIANT VAL-119.
RC   TISSUE=Lung;
RX   PubMed=12135769; DOI=10.1016/S0014-5793(02)03007-7;
RA   Guo J.-M., Zhang Y., Cheng L., Iwasaki H., Wang H., Kubota T.,
RA   Tachibana K., Narimatsu H.;
RT   "Molecular cloning and characterization of a novel member of the UDP-
RT   GalNAc:polypeptide N-acetylgalactosaminyltransferase family, pp-
RT   GalNAc-T12(1).";
RL   FEBS Lett. 524:211-218(2002).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RA   Bennett E.P.;
RL   Submitted (JAN-1999) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15164053; DOI=10.1038/nature02465;
RA   Humphray S.J., Oliver K., Hunt A.R., Plumb R.W., Loveland J.E.,
RA   Howe K.L., Andrews T.D., Searle S., Hunt S.E., Scott C.E., Jones M.C.,
RA   Ainscough R., Almeida J.P., Ambrose K.D., Ashwell R.I.S.,
RA   Babbage A.K., Babbage S., Bagguley C.L., Bailey J., Banerjee R.,
RA   Barker D.J., Barlow K.F., Bates K., Beasley H., Beasley O., Bird C.P.,
RA   Bray-Allen S., Brown A.J., Brown J.Y., Burford D., Burrill W.,
RA   Burton J., Carder C., Carter N.P., Chapman J.C., Chen Y., Clarke G.,
RA   Clark S.Y., Clee C.M., Clegg S., Collier R.E., Corby N., Crosier M.,
RA   Cummings A.T., Davies J., Dhami P., Dunn M., Dutta I., Dyer L.W.,
RA   Earthrowl M.E., Faulkner L., Fleming C.J., Frankish A.,
RA   Frankland J.A., French L., Fricker D.G., Garner P., Garnett J.,
RA   Ghori J., Gilbert J.G.R., Glison C., Grafham D.V., Gribble S.,
RA   Griffiths C., Griffiths-Jones S., Grocock R., Guy J., Hall R.E.,
RA   Hammond S., Harley J.L., Harrison E.S.I., Hart E.A., Heath P.D.,
RA   Henderson C.D., Hopkins B.L., Howard P.J., Howden P.J., Huckle E.,
RA   Johnson C., Johnson D., Joy A.A., Kay M., Keenan S., Kershaw J.K.,
RA   Kimberley A.M., King A., Knights A., Laird G.K., Langford C.,
RA   Lawlor S., Leongamornlert D.A., Leversha M., Lloyd C., Lloyd D.M.,
RA   Lovell J., Martin S., Mashreghi-Mohammadi M., Matthews L., McLaren S.,
RA   McLay K.E., McMurray A., Milne S., Nickerson T., Nisbett J.,
RA   Nordsiek G., Pearce A.V., Peck A.I., Porter K.M., Pandian R.,
RA   Pelan S., Phillimore B., Povey S., Ramsey Y., Rand V., Scharfe M.,
RA   Sehra H.K., Shownkeen R., Sims S.K., Skuce C.D., Smith M.,
RA   Steward C.A., Swarbreck D., Sycamore N., Tester J., Thorpe A.,
RA   Tracey A., Tromans A., Thomas D.W., Wall M., Wallis J.M., West A.P.,
RA   Whitehead S.L., Willey D.L., Williams S.A., Wilming L., Wray P.W.,
RA   Young L., Ashurst J.L., Coulson A., Blocker H., Durbin R.M.,
RA   Sulston J.E., Hubbard T., Jackson M.J., Bentley D.R., Beck S.,
RA   Rogers J., Dunham I.;
RT   "DNA sequence and analysis of human chromosome 9.";
RL   Nature 429:369-374(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Bone marrow;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 144-581 (ISOFORM 1).
RC   TISSUE=Colon;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [6]
RP   VARIANTS CRCS1 TRP-297; ASN-303; ASP-341; HIS-373; HIS-382; PHE-479
RP   AND MET-491, CHARACTERIZATION OF VARIANTS CRCS1 TRP-297; ASN-303;
RP   ASP-341; HIS-373; HIS-382; PHE-479 AND MET-491, AND VARIANTS GLU-3;
RP   ARG-46; VAL-119; ASN-261; ARG-272 AND LYS-552.
RX   PubMed=19617566; DOI=10.1073/pnas.0901454106;
RA   Guda K., Moinova H., He J., Jamison O., Ravi L., Natale L.,
RA   Lutterbaugh J., Lawrence E., Lewis S., Willson J.K., Lowe J.B.,
RA   Wiesner G.L., Parmigiani G., Barnholtz-Sloan J., Dawson D.W.,
RA   Velculescu V.E., Kinzler K.W., Papadopoulos N., Vogelstein B.,
RA   Willis J., Gerken T.A., Markowitz S.D.;
RT   "Inactivating germ-line and somatic mutations in polypeptide N-
RT   acetylgalactosaminyltransferase 12 in human colon cancers.";
RL   Proc. Natl. Acad. Sci. U.S.A. 106:12921-12925(2009).
RN   [7]
RP   VARIANTS CRCS1 ASN-303 AND CYS-396.
RX   PubMed=22461326; DOI=10.1002/humu.22088;
RA   Clarke E., Green R.C., Green J.S., Mahoney K., Parfrey P.S.,
RA   Younghusband H.B., Woods M.O.;
RT   "Inherited deleterious variants in GALNT12 are associated with CRC
RT   susceptibility.";
RL   Hum. Mutat. 33:1056-1058(2012).
RN   [8]
RP   INVOLVEMENT IN CRCS1.
RX   PubMed=24115450; DOI=10.1002/humu.22454;
RA   Segui N., Pineda M., Navarro M., Lazaro C., Brunet J., Infante M.,
RA   Duran M., Soto J.L., Blanco I., Capella G., Valle L.;
RT   "GALNT12 is not a major contributor of familial colorectal cancer type
RT   X.";
RL   Hum. Mutat. 35:50-52(2014).
CC   -!- FUNCTION: Catalyzes the initial reaction in O-linked
CC       oligosaccharide biosynthesis, the transfer of an N-acetyl-D-
CC       galactosamine residue to a serine or threonine residue on the
CC       protein receptor. Has activity toward non-glycosylated peptides
CC       such as Muc5AC, Muc1a and EA2, and no detectable activity with
CC       Muc2 and Muc7. Displays enzymatic activity toward the Gal-NAc-
CC       Muc5AC glycopeptide, but no detectable activity to mono-GalNAc-
CC       glycosylated Muc1a, Muc2, Muc7 and EA2. May play an important role
CC       in the initial step of mucin-type oligosaccharide biosynthesis in
CC       digestive organs.
CC   -!- CATALYTIC ACTIVITY: UDP-N-acetyl-alpha-D-galactosamine +
CC       polypeptide = UDP + N-acetyl-alpha-D-galactosaminyl-polypeptide.
CC       {ECO:0000269|PubMed:12135769}.
CC   -!- COFACTOR:
CC       Name=Mn(2+); Xref=ChEBI:CHEBI:29035; Evidence={ECO:0000250};
CC   -!- PATHWAY: Protein modification; protein glycosylation.
CC   -!- SUBCELLULAR LOCATION: Golgi apparatus membrane {ECO:0000250};
CC       Single-pass type II membrane protein {ECO:0000250}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q8IXK2-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q8IXK2-2; Sequence=VSP_011217;
CC         Note=No experimental confirmation available.;
CC   -!- TISSUE SPECIFICITY: Widely expressed at different levels of
CC       expression. Highly expressed in digestive organs such as small
CC       intestine, stomach, pancreas and colon. Expressed at intermediate
CC       level in testis, thyroid gland and spleen. Weakly expressed in
CC       whole brain, cerebral cortex, cerebellum, fetal brain, bone
CC       marrow, thymus, leukocytes, heart, skeletal muscle, liver, lung,
CC       esophagus, kidney, adrenal gland, mammary gland, uterus, placenta,
CC       ovary and prostate. {ECO:0000269|PubMed:12135769}.
CC   -!- DOMAIN: There are two conserved domains in the glycosyltransferase
CC       region: the N-terminal domain (domain A, also called GT1 motif),
CC       which is probably involved in manganese coordination and substrate
CC       binding and the C-terminal domain (domain B, also called
CC       Gal/GalNAc-T motif), which is probably involved in catalytic
CC       reaction and UDP-Gal binding. {ECO:0000250}.
CC   -!- DOMAIN: The ricin B-type lectin domain binds to GalNAc and
CC       contributes to the glycopeptide specificity. {ECO:0000250}.
CC   -!- DISEASE: Colorectal cancer 1 (CRCS1) [MIM:608812]: A complex
CC       disease characterized by malignant lesions arising from the inner
CC       wall of the large intestine (the colon) and the rectum. Genetic
CC       alterations are often associated with progression from
CC       premalignant lesion (adenoma) to invasive adenocarcinoma. Risk
CC       factors for cancer of the colon and rectum include colon polyps,
CC       long-standing ulcerative colitis, and genetic family history.
CC       {ECO:0000269|PubMed:19617566, ECO:0000269|PubMed:22461326,
CC       ECO:0000269|PubMed:24115450}. Note=Disease susceptibility is
CC       associated with variations affecting the gene represented in this
CC       entry. The role of GALNT12 in colon cancer susceptibility is
CC       however subject to discussion: studies on 103 probants with
CC       colorectal cancer 1 (CRCS1) suggest that it does not act as a
CC       major contributor of CRCS1 (PubMed:24115450).
CC       {ECO:0000269|PubMed:24115450}.
CC   -!- SIMILARITY: Belongs to the glycosyltransferase 2 family. GalNAc-T
CC       subfamily. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAB15027.1; Type=Erroneous initiation; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=Functional Glycomics Gateway - GTase;
CC       Note=Polypeptide N-acetylgalactosaminyltransferase 12;
CC       URL="http://www.functionalglycomics.org/glycomics/molecule/jsp/glycoEnzyme/viewGlycoEnzyme.jsp?gbpId=gt_hum_495";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AB078146; BAC07181.1; -; mRNA.
DR   EMBL; AJ132365; CAC80100.2; -; mRNA.
DR   EMBL; AL136084; CAI17042.1; -; Genomic_DNA.
DR   EMBL; BC013945; AAH13945.1; -; mRNA.
DR   EMBL; AK024865; BAB15027.1; ALT_INIT; mRNA.
DR   CCDS; CCDS6737.1; -. [Q8IXK2-1]
DR   RefSeq; NP_078918.3; NM_024642.4. [Q8IXK2-1]
DR   RefSeq; XP_006717350.1; XM_006717287.1.
DR   UniGene; Hs.47099; -.
DR   ProteinModelPortal; Q8IXK2; -.
DR   SMR; Q8IXK2; -.
DR   BioGrid; 122816; 25.
DR   IntAct; Q8IXK2; 11.
DR   STRING; 9606.ENSP00000364150; -.
DR   CAZy; CBM13; Carbohydrate-Binding Module Family 13.
DR   CAZy; GT27; Glycosyltransferase Family 27.
DR   iPTMnet; Q8IXK2; -.
DR   PhosphoSitePlus; Q8IXK2; -.
DR   SwissPalm; Q8IXK2; -.
DR   BioMuta; GALNT12; -.
DR   DMDM; 84028209; -.
DR   EPD; Q8IXK2; -.
DR   MaxQB; Q8IXK2; -.
DR   PaxDb; Q8IXK2; -.
DR   PeptideAtlas; Q8IXK2; -.
DR   PRIDE; Q8IXK2; -.
DR   DNASU; 79695; -.
DR   Ensembl; ENST00000375011; ENSP00000364150; ENSG00000119514. [Q8IXK2-1]
DR   GeneID; 79695; -.
DR   KEGG; hsa:79695; -.
DR   UCSC; uc004ayz.3; human. [Q8IXK2-1]
DR   CTD; 79695; -.
DR   DisGeNET; 79695; -.
DR   GeneCards; GALNT12; -.
DR   H-InvDB; HIX0008226; -.
DR   HGNC; HGNC:19877; GALNT12.
DR   HPA; HPA048292; -.
DR   MalaCards; GALNT12; -.
DR   MIM; 608812; phenotype.
DR   MIM; 610290; gene.
DR   neXtProt; NX_Q8IXK2; -.
DR   OpenTargets; ENSG00000119514; -.
DR   PharmGKB; PA134929192; -.
DR   eggNOG; KOG3736; Eukaryota.
DR   eggNOG; ENOG410XPMK; LUCA.
DR   GeneTree; ENSGT00760000118828; -.
DR   HOGENOM; HOG000038227; -.
DR   HOVERGEN; HBG051699; -.
DR   InParanoid; Q8IXK2; -.
DR   KO; K00710; -.
DR   OMA; EIRYNTH; -.
DR   OrthoDB; EOG091G085O; -.
DR   PhylomeDB; Q8IXK2; -.
DR   TreeFam; TF352660; -.
DR   BRENDA; 2.4.1.41; 2681.
DR   Reactome; R-HSA-913709; O-linked glycosylation of mucins.
DR   UniPathway; UPA00378; -.
DR   GenomeRNAi; 79695; -.
DR   PRO; PR:Q8IXK2; -.
DR   Proteomes; UP000005640; Chromosome 9.
DR   Bgee; ENSG00000119514; -.
DR   CleanEx; HS_GALNT12; -.
DR   ExpressionAtlas; Q8IXK2; baseline and differential.
DR   Genevisible; Q8IXK2; HS.
DR   GO; GO:0000139; C:Golgi membrane; TAS:Reactome.
DR   GO; GO:0016021; C:integral component of membrane; IEA:UniProtKB-KW.
DR   GO; GO:0030246; F:carbohydrate binding; IEA:UniProtKB-KW.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0004653; F:polypeptide N-acetylgalactosaminyltransferase activity; TAS:Reactome.
DR   GO; GO:0016266; P:O-glycan processing; TAS:Reactome.
DR   Gene3D; 3.90.550.10; -; 1.
DR   InterPro; IPR001173; Glyco_trans_2-like.
DR   InterPro; IPR029044; Nucleotide-diphossugar_trans.
DR   InterPro; IPR000772; Ricin_B_lectin.
DR   Pfam; PF00535; Glycos_transf_2; 1.
DR   Pfam; PF00652; Ricin_B_lectin; 1.
DR   SMART; SM00458; RICIN; 1.
DR   SUPFAM; SSF50370; SSF50370; 1.
DR   SUPFAM; SSF53448; SSF53448; 1.
DR   PROSITE; PS50231; RICIN_B_LECTIN; 1.
PE   1: Evidence at protein level;
KW   Alternative splicing; Complete proteome; Disease mutation;
KW   Disulfide bond; Glycosyltransferase; Golgi apparatus; Lectin;
KW   Manganese; Membrane; Metal-binding; Polymorphism; Reference proteome;
KW   Signal-anchor; Transferase; Transmembrane; Transmembrane helix.
FT   CHAIN         1    581       Polypeptide N-
FT                                acetylgalactosaminyltransferase 12.
FT                                /FTId=PRO_0000059128.
FT   TOPO_DOM      1     19       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM     20     37       Helical; Signal-anchor for type II
FT                                membrane protein. {ECO:0000255}.
FT   TOPO_DOM     38    581       Lumenal. {ECO:0000255}.
FT   DOMAIN      445    577       Ricin B-type lectin.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00174}.
FT   REGION      135    244       Catalytic subdomain A.
FT   REGION      304    366       Catalytic subdomain B.
FT   METAL       228    228       Manganese. {ECO:0000250}.
FT   METAL       230    230       Manganese. {ECO:0000250}.
FT   METAL       363    363       Manganese. {ECO:0000250}.
FT   BINDING     176    176       Substrate. {ECO:0000250}.
FT   BINDING     205    205       Substrate. {ECO:0000250}.
FT   BINDING     335    335       Substrate. {ECO:0000250}.
FT   BINDING     371    371       Substrate. {ECO:0000250}.
FT   DISULFID    125    358       {ECO:0000255|PROSITE-ProRule:PRU00174}.
FT   DISULFID    349    422       {ECO:0000255|PROSITE-ProRule:PRU00174}.
FT   DISULFID    458    479       {ECO:0000255|PROSITE-ProRule:PRU00174}.
FT   DISULFID    506    521       {ECO:0000255|PROSITE-ProRule:PRU00174}.
FT   DISULFID    547    566       {ECO:0000255|PROSITE-ProRule:PRU00174}.
FT   VAR_SEQ       1    309       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_011217.
FT   VARIANT       3      3       G -> E. {ECO:0000269|PubMed:19617566}.
FT                                /FTId=VAR_064352.
FT   VARIANT      46     46       G -> R (in dbSNP:rs10987768).
FT                                {ECO:0000269|PubMed:19617566}.
FT                                /FTId=VAR_064353.
FT   VARIANT     119    119       E -> V (in dbSNP:rs1137654).
FT                                {ECO:0000269|PubMed:12135769,
FT                                ECO:0000269|PubMed:19617566}.
FT                                /FTId=VAR_064354.
FT   VARIANT     261    261       D -> N (in dbSNP:rs41306504).
FT                                {ECO:0000269|PubMed:19617566}.
FT                                /FTId=VAR_064355.
FT   VARIANT     272    272       G -> R (in dbSNP:rs367645298).
FT                                {ECO:0000269|PubMed:19617566}.
FT                                /FTId=VAR_064356.
FT   VARIANT     297    297       R -> W (in CRCS1; germline mutation;
FT                                partial loss of activity;
FT                                dbSNP:rs149726976).
FT                                {ECO:0000269|PubMed:19617566}.
FT                                /FTId=VAR_064357.
FT   VARIANT     303    303       D -> N (in CRCS1; germline mutation;
FT                                reduction of activity;
FT                                dbSNP:rs145236923).
FT                                {ECO:0000269|PubMed:19617566,
FT                                ECO:0000269|PubMed:22461326}.
FT                                /FTId=VAR_064358.
FT   VARIANT     341    341       E -> D (in CRCS1; somatic mutation; loss
FT                                of activity).
FT                                {ECO:0000269|PubMed:19617566}.
FT                                /FTId=VAR_064359.
FT   VARIANT     373    373       R -> H (in CRCS1; germline mutation;
FT                                partial loss of activity).
FT                                {ECO:0000269|PubMed:19617566}.
FT                                /FTId=VAR_064360.
FT   VARIANT     382    382       R -> H (in CRCS1; germline mutation; loss
FT                                of activity; dbSNP:rs868590153).
FT                                {ECO:0000269|PubMed:19617566}.
FT                                /FTId=VAR_064361.
FT   VARIANT     396    396       Y -> C (in CRCS1).
FT                                {ECO:0000269|PubMed:22461326}.
FT                                /FTId=VAR_068509.
FT   VARIANT     479    479       C -> F (in CRCS1; somatic mutation; loss
FT                                of activity).
FT                                {ECO:0000269|PubMed:19617566}.
FT                                /FTId=VAR_064362.
FT   VARIANT     491    491       T -> M (in CRCS1; germline mutation; loss
FT                                of activity; dbSNP:rs267606840).
FT                                {ECO:0000269|PubMed:19617566}.
FT                                /FTId=VAR_064363.
FT   VARIANT     552    552       R -> K. {ECO:0000269|PubMed:19617566}.
FT                                /FTId=VAR_064364.
SQ   SEQUENCE   581 AA;  66938 MW;  8C001D58E103A523 CRC64;
     MWGRTARRRC PRELRRGREA LLVLLALLAL AGLGSVLRAQ RGAGAGAAEP GPPRTPRPGR
     REPVMPRPPV PANALGARGE AVRLQLQGEE LRLQEESVRL HQINIYLSDR ISLHRRLPER
     WNPLCKEKKY DYDNLPRTSV IIAFYNEAWS TLLRTVYSVL ETSPDILLEE VILVDDYSDR
     EHLKERLANE LSGLPKVRLI RANKREGLVR ARLLGASAAR GDVLTFLDCH CECHEGWLEP
     LLQRIHEEES AVVCPVIDVI DWNTFEYLGN SGEPQIGGFD WRLVFTWHTV PERERIRMQS
     PVDVIRSPTM AGGLFAVSKK YFEYLGSYDT GMEVWGGENL EFSFRIWQCG GVLETHPCSH
     VGHVFPKQAP YSRNKALANS VRAAEVWMDE FKELYYHRNP RARLEPFGDV TERKQLRDKL
     QCKDFKWFLE TVYPELHVPE DRPGFFGMLQ NKGLTDYCFD YNPPDENQIV GHQVILYLCH
     GMGQNQFFEY TSQKEIRYNT HQPEGCIAVE AGMDTLIMHL CEETAPENQK FILQEDGSLF
     HEQSKKCVQA ARKESSDSFV PLLRDCTNSD HQKWFFKERM L
//
